1. Home
  2. KURA

as of 12-31-2025 3:52pm EST

$10.36
+$0.13
+1.32%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 1.0B IPO Year: N/A
Target Price: $25.00 AVG Volume (30 days): 1.7M
Analyst Decision: Buy Number of Analysts: 11
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.48 EPS Growth: N/A
52 Week Low/High: $5.41 - $12.49 Next Earning Date: 11-04-2025
Revenue: $104,029,000 Revenue Growth: N/A
Revenue Growth (this year): 138.16% Revenue Growth (next year): 66.98%

AI-Powered KURA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 71.33%
71.33%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Kura Oncology Inc. (KURA)

Burrows Francis

Chief Scientific Officer

Sell
KURA Dec 18, 2025

Avg Cost/Share

$9.78

Shares

23,726

Total Value

$231,931.14

Owned After

33,735

SEC Form 4

Sell
KURA Dec 9, 2025

Avg Cost/Share

$10.98

Shares

10,000

Total Value

$109,764.00

Owned After

23,983

SEC Form 4

Share on Social Networks: